NextPharma Technologies, also known as NextPharma San Diego (and sometimes known as Bioserv) provides contract manufacturing services to biotechnology, pharmaceutical, diagnostic, and medical device companies. Its facilities can prepare the small batches of biological drugs and placebos used in clinical trials. It can produce solid, liquid, and semi-solid products, as well as injectable drugs. It also offers clinical trial support services and pharmaceutical logistics services. The company's customers include both small and large multinational health care corporations. NextPharma Technologies is the US subsidiary of the UK's NextPharma Technologies Holding Ltd.

Rowett Research Services (RRS) will supply the technology, thanks to its research parent, the Rowett Institute. It will even throw in marketing services and project management. All RRS needs are companies interested in commercializing new ideas and products. Its primary focuses are nutrition issues and outpatient health care studies, such as antimicrobial agents and antioxidants. Founded in 1988, RRS works with public and private partners in the pharmaceutical, biotechnology, food, and agricultural industries to bring the research underway at the Rowett Institute to the marketplace.

Entelos using its PhysioLab technology, the company develops computer models of diseases that drug makers and other researchers can use to design drugs and other therapies more effectively. The disease models integrate known genomic and proteomic data with physiologic, environmental, and other information collected from clinical trials, case studies, and other sources. Entelos has developed PhysioLab models for asthma, diabetes, obesity, and rheumatoid arthritis. The models are built in partnership with such firms as Eli Lilly, PDL Biopharma, and UCB Pharma.

FibroGen, Inc. company is focused on developing and commercializing treatments for fibrosis, anemia, diabetes, and cancer, as well as producing recombinant human collagens and synthetic gelatins. FibroGen has several products in clinical development, including: FG-3019, a monoclonal antibody that may treat a variety of conditions including diabetic nephropathy; FG-2216, an orally administered small molecule drug in development for the treatment of anemia; FG-5017, a recombinant version of human collagen; and FG-5009, a synthetic gelatin molecule designed to stabilize vaccines and biologics. The company commenced lab operations in 1995.

Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts. Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000.

TRANSGENE S.A. company was founded in 1979 and is based in Strasbourg, France. Transgene S.A. is a subsidiary of Merieux Alliance. Transgene S.A., a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s products primarily include TG 4001/R3484, an immunotherapy targeting anti-infectious for human papilloma virus-associated pathologies, which completed Phase IIa trials; TG 4010, a cancer vaccine primarily for non small cell lung cancer, which is in Phase IIb trials; TG 1042, an immune enhancement gene therapy for cutaneous B-cell lymphoma, which is in Phase II trials; TG 4040, an anti-infectious therapeutic vaccine for chronic hepatitis C infection, which is in Phase I trials; and TG 4023, a preclinical suicide gene candidate for the treatment of 5-FU-sensitive tumors. It also offers a package of services relating to molecular biology, development, and biomanufacturing that include design and construction of new vaccines; development and/or adaptation of production process; development and/or adaptation of quality control assays; production and control of starting material for pharmaceutical and clinical development; and manufacturing material for clinical trials. Transgene S.A. has collaboration agreements with Roche, Association Francaise contre les Myopathies, and MIRUS; manufacturing and subcontracting agreements with International AIDS Vaccine Initiative, Innogenetics, Agence Nationale de Recherche contre le SIDA, Institut National de la Sante et de la Recherche Medicale, and EUROVACC; and licensing agreements with Merck, Imperial Cancer Research Technology, Ajinomoto, Aventis, and Cayla.

Precision Therapeutics, Inc. company was founded in 1995 and is headquartered in Pittsburgh, Pennsylvania. Precision Therapeutics, Inc., a diagnostics services company, engages in the development and delivery of treatment support tools for physicians and cancer patients in the United States and Canada. The company develops predictive drug response tests, which include ChemoFx, a drug response marker test that quantifies a cancer patient's probable tumor response to various chemotherapeutic and biologic agents and provides sensitivity and resistance information, such as tumor progression, increased side effects, accumulated toxicity, development of cross-resistance, decreased efficacy of future treatments, and decreased quality of life. It offers physicians and patients with clinical information to personalize cancer treatments.

PetMed Express, Inc. was founded in 1996 and is headquartered in Pompano Beach, Florida. PetMed Express, Inc. (PetMed) and its subsidiaries, doing business as 1-800-PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses direct to the consumer. The Company markets its products through national television, online, and direct mail/print advertising campaigns. PetMed offers a selection of products for dogs, cats, and horses. As of March 31, 2009, its product line contains approximately 750 stock keeping units (skus). These products include brands of medication, such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx and Rimadyl.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.